Literature DB >> 27152166

The physiological relevance of functional selectivity in dopamine signalling.

N M Urs1, M G Caron2.   

Abstract

We sought to determine the role of functionally selective dopamine (DA) signalling pathways (G protein or β-arrestin) in DA-dependent behaviours. Mice that were globally deficient for β-arrestins or mice deficient in GSK3β in D2 receptor (D2R)-expressing neurons were used to investigate the role of functional selectivity in DA-dependent behaviours such as locomotor activity and conditioned place preference (CPP). Wild-type or knockout mice were injected with drugs such as morphine and amphetamine, which are known to increase DA levels in the brain and to induce a hyper-locomotor response and CPP. Unlike β-arrestin1 (βarr1)-deficient mice, mice globally deficient for β-arrestin2 (βarr2) mount a reduced hyperlocomotor response to either morphine or amphetamine. However, mice deficient in GSK3β in D2R-expressing neurons show a significantly reduced locomotor response to only amphetamine but not morphine. Interestingly, all mice tested show a normal CPP response to either morphine or amphetamine. β-arrestin-mediated DA receptor signalling has an important role in the locomotor response, but not CPP, to drugs such as morphine and amphetamine, demonstrating a functional selectivity of DA-dependent behaviours in mice. It is likely that G-protein-dependent signalling through DA receptors mediates the CPP response.

Entities:  

Keywords:  biased signalling; Parkinson's disease; schizophrenia; drug addiction

Year:  2014        PMID: 27152166      PMCID: PMC4850582          DOI: 10.1038/ijosup.2014.3

Source DB:  PubMed          Journal:  Int J Obes Suppl        ISSN: 2046-2166


  26 in total

1.  Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.

Authors:  John A Allen; Julianne M Yost; Vincent Setola; Xin Chen; Maria F Sassano; Meng Chen; Sean Peterson; Prem N Yadav; Xi-ping Huang; Bo Feng; Niels H Jensen; Xin Che; Xu Bai; Stephen V Frye; William C Wetsel; Marc G Caron; Jonathan A Javitch; Bryan L Roth; Jian Jin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 2.  Functional selectivity and classical concepts of quantitative pharmacology.

Authors:  Jonathan D Urban; William P Clarke; Mark von Zastrow; David E Nichols; Brian Kobilka; Harel Weinstein; Jonathan A Javitch; Bryan L Roth; Arthur Christopoulos; Patrick M Sexton; Keith J Miller; Michael Spedding; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2006-06-27       Impact factor: 4.030

3.  Enhanced morphine analgesia in mice lacking beta-arrestin 2.

Authors:  L M Bohn; R J Lefkowitz; R R Gainetdinov; K Peppel; M G Caron; F T Lin
Journal:  Science       Date:  1999-12-24       Impact factor: 47.728

Review 4.  The neurobiology of slow synaptic transmission.

Authors:  P Greengard
Journal:  Science       Date:  2001-11-02       Impact factor: 47.728

5.  beta-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation.

Authors:  D A Conner; M A Mathier; R M Mortensen; M Christe; S F Vatner; C E Seidman; J G Seidman
Journal:  Circ Res       Date:  1997-12       Impact factor: 17.367

6.  Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice.

Authors:  Jean-Martin Beaulieu; Tatyana D Sotnikova; Raul R Gainetdinov; Marc G Caron
Journal:  J Biol Chem       Date:  2006-09-05       Impact factor: 5.157

7.  Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7.

Authors:  Sudarshan Rajagopal; Jihee Kim; Seungkirl Ahn; Stewart Craig; Christopher M Lam; Norma P Gerard; Craig Gerard; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-17       Impact factor: 11.205

8.  Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs.

Authors:  Helen S Bateup; Per Svenningsson; Mahomi Kuroiwa; Shiaoching Gong; Akinori Nishi; Nathaniel Heintz; Paul Greengard
Journal:  Nat Neurosci       Date:  2008-07-11       Impact factor: 24.884

9.  Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.

Authors:  Nikhil M Urs; Joshua C Snyder; Jacob P R Jacobsen; Sean M Peterson; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-27       Impact factor: 11.205

10.  Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus.

Authors:  S Srinivas; T Watanabe; C S Lin; C M William; Y Tanabe; T M Jessell; F Costantini
Journal:  BMC Dev Biol       Date:  2001-03-27       Impact factor: 1.978

View more
  6 in total

1.  The dopamine D2 receptor can directly recruit and activate GRK2 without G protein activation.

Authors:  Thomas F Pack; Margo I Orlen; Caroline Ray; Sean M Peterson; Marc G Caron
Journal:  J Biol Chem       Date:  2018-02-27       Impact factor: 5.157

2.  Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists.

Authors:  Wei Xu; Xiaozhao Wang; Aaron M Tocker; Peng Huang; Maarten E A Reith; Lee-Yuan Liu-Chen; Amos B Smith; Sandhya Kortagere
Journal:  ACS Chem Neurosci       Date:  2016-11-23       Impact factor: 4.418

Review 3.  Arresting the Development of Addiction: The Role of β-Arrestin 2 in Drug Abuse.

Authors:  Kirsten A Porter-Stransky; David Weinshenker
Journal:  J Pharmacol Exp Ther       Date:  2017-03-16       Impact factor: 4.030

4.  Role of Efficacy as a Determinant of Locomotor Activation by Mu Opioid Receptor Ligands in Female and Male Mice.

Authors:  Edna J Santos; Matthew L Banks; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2022-04-30       Impact factor: 4.402

Review 5.  Targeting β-Arrestins in the Treatment of Psychiatric and Neurological Disorders.

Authors:  Sharonda S Harris; Nikhil M Urs
Journal:  CNS Drugs       Date:  2021-03-02       Impact factor: 5.749

6.  Dual pancreatic adrenergic and dopaminergic signaling as a therapeutic target of bromocriptine.

Authors:  Despoina Aslanoglou; Suzanne Bertera; Laura Friggeri; Marta Sánchez-Soto; Jeongkyung Lee; Xiangning Xue; Ryan W Logan; J Robert Lane; Vijay K Yechoor; Peter J McCormick; Jens Meiler; R Benjamin Free; David R Sibley; Rita Bottino; Zachary Freyberg
Journal:  iScience       Date:  2022-07-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.